Forensic Analysis · Technology / Software · as of Sep 24, 2026
Amphenol Corp /De/ (APH)
A forensic read on Amphenol Corp /De/ built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
A · High-quality
Forensic grade
Safe
Financial health
13.8
Distress distance
Clean
Earnings quality
2
Forensic signals
37.3
P / E (ttm)
31.8%
ROE
$202.7B
Market cap
0.97%
Dividend yield
51.7%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Amphenol Corp /De/ earns an A (High-quality) forensic quality grade, and its balance-sheet distress test reads 13.8, placing it in the Safe zone. 2 forensic signals were flagged in its latest SEC filings, led by share-count dilution.
What the filings flag
+1.5%/yr
FY2023–FY2025
Share-count dilution.Diluted share count changed +3% over the last 2 years to FY2025 (+1.5%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~1.5% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~3%.
+28.5%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +28.5% relative to their own average in FY2025 — scaled by NOA itself, not by total assets, which is what the Forensic Screens card's own accrual row divides by. Accruals are building sharply, and much of it is accounted for. The build is led by receivables up +43% against revenue +52% and inventory up +35% against +45% in cost of sales. That build tracks a +52% revenue year: net operating assets grew +33% and receivables +43%, so the balance sheet is carrying more volume rather than getting heavier per dollar of sales — the accrual build is funding demand the company is shipping, not earnings running ahead of collection. A cash-flow measure on the same base disagrees: reported earnings ran behind operating cash by 7% of net operating assets, against an accruals ratio of 28.5%. The two are computed differently: the accruals ratio is the change in net operating assets over average net operating assets, while the cash-flow figure is net income less operating cash flow over that same average. Read them as two results, not one.
Key fundamentals
Latest Revenue$23.09B
Revenue Growth YoY+51.7%
Revenue CAGR (2yr)+35.6%
Net Margin18.5%
Free Cash Flow$4.38B
Return on Equity31.8%
Debt / Equity1.16x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Amphenol Corp /De/'s actual 10-K/10-Q/8-K filings?